UKX

(2S)-2-(2-oxidanylidenepyrrolidin-1-yl)butanamide

Created:	2023-06-09
Last modified:	2024-05-01

Find Related PDB Entry
7 entries where UKX is found as a standalone ligand

Find related ligands: Help
Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	26
Chiral Atom Count	1
Bond Count	26
Aromatic Bond Count	0

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	(2S)-2-(2-oxidanylidenepyrrolidin-1-yl)butanamide
Synonyms	levetiracetam
Systematic Name (OpenEye OEToolkits)	(2~{S})-2-(2-oxidanylidenepyrrolidin-1-yl)butanamide
Formula	C₈ H₁₄ N₂ O₂
Molecular Weight	170.209
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	CACTVS	3.385	CC[CH](N1CCCC1=O)C(N)=O
SMILES	OpenEye OEToolkits	2.0.7	CCC(C(=O)N)N1CCCC1=O
Canonical SMILES	CACTVS	3.385	CC[C@H](N1CCCC1=O)C(N)=O
Canonical SMILES	OpenEye OEToolkits	2.0.7	CC[C@@H](C(=O)N)N1CCCC1=O
InChI	InChI	1.06	InChI=1S/C8H14N2O2/c1-2-6(8(9)12)10-5-3-4-7(10)11/h6H,2-5H2,1H3,(H2,9,12)/t6-/m0/s1
InChIKey	InChI	1.06	HPHUVLMMVZITSG-LURJTMIESA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

DrugBank ID	DB01202
Name	Levetiracetam
Groups	investigational approved
Description	Levetiracetam is a drug within the pyrrolidine class that is used to treat various types of seizures stemming from epileptic disorders. It was first approved for use in the United States in 1999 and is structurally and mechanistically unrelated to other anti-epileptic drugs (AEDs).[L8606,L8600,L8615] Levetiracetam possesses a wide therapeutic index[L8615,A185918] and little-to-no potential to produce, or be subject to, pharmacokinetic interactions[L8606,L8600,L8615] - these characteristics make it a desirable choice over other AEDs, a class of drugs notorious for having generally narrow therapeutic indexes and a propensity for involvement in drug interactions.[A185927]
Synonyms	Levetiracetam Levetiracetamum Lévétiracetam Levetiracetame
Brand Names	Auro-levetiracetam Levetiracetam Sun Nu-levetiracetam Levetiracetam 250 mg Levetiracetam Extended-Release Pro-levetiracetam - 500 Levertiracetam Apo-levetiracetam Novo-levetiracetam Levetiracetam Teva Elepsia XR 1500 mg Keppra XR Elepsia XR 1000 mg Roweepra XR Tva-levetiracetam Levetiracetam 750 mg Levetiracetam 1000 mg Levetiracetam extended-release Elepsia XR Bio-levetiracetam Pro-levetiracetam - 250 PHL-levetiracetam Levetiracetam Hospira Levetiracetam in Sodium Chloride Keppra Mint-levetiracetam Solution Dom-levetiracetam Van-levetiracetam Jamp Levetiracetam Tablets Ava-levetiracetam Sandoz Levetiracetam Levetiracetam Accord Priva-levetiracetam Levetiracetam Ratiopharm Levetiracetam Injection USP Levetiractam Ach-levetiracetam Pharma-levetiracetam Levetiracetam Actavis Group LEVETIRACETAM solution Matever Abbott-levetiracetam Ag-levetiracetam LEVETIRACETAM Extended-release Nra-levetiracetam PMS-levetiracetam Levetiracetam Extended-release Levetiracetam ER Roweepra Teva-levetiracetam Spritam Levetiracetam Micro Levetiracetam Pro-levetiracetam - 750 Ran-levetiracetam Mint-levetiracetam Nat-levetiracetam Levetiracetam Levetiracetam Riva-levetiracetam Pdp-levetiracetam M-levetiracetam Levetiracetam Actavis Jamp-levetiracetam Torrent-levetiracetam Levetiracetam Extended Release
Indication	Levetiracetam is indicated as an adjunctive therapy in the treatment of partial onset seizures in epileptic patients who are one month of age and older. Additionally, it is indicated as an adjunct in the treatment of myoclonic seizures in patients with juvenile myoclonic epilepsy who are 12 years of age and older, and in primary generalized tonic-clonic seizures in patients with idiopathic generalized epilepsy who are 6 years of age and older.[L8606] Levetiracetam is also available as an orally dissolvable tablet that is indicated as an adjunct in the treatment of partial onset seizures in patients with epilepsy who are 4 years of age and older and weigh more than 20kg.[L8609]
Categories	Acetamides Amides Anticonvulsants Central Nervous System Agents Central Nervous System Depressants Decreased Central Nervous System Disorganized Electrical Activity Miscellaneous Anticonvulsants Nervous System P-glycoprotein substrates Pyrrolidines Pyrrolidinones
ATC-Code	N03AX14
CAS number	102767-28-2

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

Name	Target Sequence	Pharmacological Action	Actions
Voltage-dependent N-type calcium channel subunit alpha-1B	MVRFGDELGGRYGGPGGGERARGGGAGGAGGPGPGGLQPGQRVLYKQSIA...	unknown	inhibitor
Synaptic vesicle glycoprotein 2A	MEEGFRDRAAFIRGAKDIAKEVKKHAAKKVVKGLDRVQDEYSRRSYSRFE...	unknown	agonist
5-hydroxytryptamine receptor 3A	MLLWVQQALLALLLPTLLAQGEARRSRNTTRPALLRLSDYLLTNYRKGVR...	unknown	antagonist
ATP-dependent translocase ABCB1	MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLY...	unknown	substrate

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource Name	Reference
Pharos	CHEMBL1286
PubChem	5284583
ChEMBL	CHEMBL1286
ChEBI	CHEBI:6437
CCDC/CSD	XOGMOX, YASGAC01, OMIVUB09, OFIQUR04, OFIQUR03, OFIQUR08, OFIQUR09, YASGAC, OFIQUR05, OFIQUR06, OMIVUB03, OMIVUB05, OMIVUB04, OMIVUB08, OFIQUR10, XOGMUD, OFIQUR12, ROQLEQ, XOGNIS, XOGPAM, OFIQUR, OFIQUR02, XOGMIR, ISUNAN, OFIQUR13, OMIVUB, XOGPEQ, OFIQUR07, OMIVUB02, OFIQUR14, OFIREC, OMIVUB06, YAMQAH, OFIQUR01, XOGNOY, XOGNEO, XOGNUE, OFIQUR11, OMIVUB01, OMIVUB07, ISUMUG, ISUMOA, ROQMAN
COD	4502986, 4511597, 4510876, 4510879, 2105492, 4510871, 4502988, 2202514, 2105494, 2105493, 7246751